Ricoh sells Ricoh 3D for Healthcare patient-specific device business to newly formed Myrava, Inc.

Ricoh USA has sold Ricoh 3D for Healthcare to Myrava, Inc., a new company focused on personalized medical devices and point-of-care manufacturing for US healthcare providers. Myrava is led by Gary Turner, formerly Vice President and General Manager of Ricoh 3D for Healthcare, LLC. The unit produces FDA-cleared, patient-specific medical devices and was only converted into a standalone legal entity in 2025, after operating internally as Ricoh's 3D medical manufacturing center. Deal terms were not disclosed.

Ricoh framed the divestiture as sharpening its focus on process automation, workplace experience, and business process services, saying patient-specific device manufacturing sits outside the scope of those priorities despite healthcare remaining a growth area for the company. The move fits a recurring pattern in medical additive manufacturing, where large diversified suppliers test a specialized clinical AM adjacency, then spin it out once it requires dedicated regulatory expertise, hospital relationships, and standalone capital rather than shared enterprise infrastructure. For Ricoh, the exit narrows its healthcare exposure to administrative and operational services rather than device production.

For Myrava, independence removes internal competition for capital against Ricoh's core print and imaging businesses, but it now carries the full cost of FDA compliance, point-of-care manufacturing operations, and provider partnerships without a parent's balance sheet behind it.